

## Errata

During FY 2024, FDA received an inquiry that alerted us to certain discrepancies in our Advisory Committee Vacancies and Public Disclosures Report for past fiscal years. Upon review, FDA determined that some reports included a limited number of inaccurate figures in Table 2, primarily due to data entry and tabulation errors. The revised tables are included below and corrections are marked in red. We have instituted an additional layer of review as a quality control measure and will be exploring additional process improvements for metric reporting.

## FY 2016

**Table 2 - 712(e)(1)(D) Number of Meetings, Persons Contacted, Persons Contacted Who Did Not Serve, Participants, and Waivers Granted FY 2016**

		Number of Meetings	# of persons contacted (attending and not attending)*	# of persons contacted and not serving due to potential conflicts of interest	# of persons contacted and not serving due to reasons other than potential conflicts of interest	Total Number of Meeting Participants Attending (voting & nonvoting)*	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
<b>FDA TOTAL</b>		<b>64</b>	<del>1770</del> <b>1778</b>	91(5%)	638 (36%)	1049	8 (0.76%)	1041	99.24%
Committee Name	Meeting Date	Number of Meetings	# of persons contacted (attending and not attending)*	# of persons contacted and not serving due to potential conflicts of interest	# of persons contacted and not serving due reasons other than potential conflicts of interest	Total Number of Meeting Participants Attending (voting & nonvoting)*	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total meeting Participants with no waivers	% of Meeting Participants <u>Not</u> Issued Waivers
<b>OFFICE OF THE COMMISSIONER</b>		<b>5</b>	<b>111</b>	2 (2%)	<del>28 (25%)</del> <b>27 (24%)</b>	<b>82</b>	<b>0 (0%)</b>	<b>82</b>	<b>100.00%</b>
Science Board to the Food and Drug Administration	11/18/2015	1	20	0	7	13	0	13	100.00%
Science Board to the Food and Drug Administration	3/1/2016	1	24	1	3	20	0	20	100.00%
Pediatric Advisory Committee	4/12/2016	1	22	0	3	19	0	19	100.00%
Pediatric Advisory Committee	9/14/2016	1	29	1	<del>11</del> <b>10</b>	18	0	18	100.00%
Risk Communication Advisory Committee(RCAC)	2/16-17/2016	1	16	0	4	12	0	12	100.00%
<b>CENTER FOR BIOLOGICS EVALUATION &amp; RESEARCH</b>		<b>9</b>	<b>175</b>	<b>8 (4%)</b>	<b>38 (22%)</b>	<b>129</b>	<b>1 (0.78%)</b>	<b>128</b>	<b>99.22%</b>
Allergenic Products	1/21/2016	1	12	1	1	10	0	10	100.00%
Blood Products	6/20/2016	0	14	0	4	10	0	10	100.00%
Cellular, Tissue and Gene Therapies//Joint Meeting with Oncologic Drugs	11/18/2015	1	50	2	21	27	0	27	100.00%
Cellular, Tissue and Gene Therapies	2/16/2016	1	13	0	1	12	0	12	100.00%
Cellular Tissue and Gene Therapy Advisory Committee	7/26/2016	1	11	0	2	9	0	9	100.00%
Cellular Tissue and Gene Therapy Advisory Committee	9/7/2016	1	11	0	1	10	0	10	100.00%
Vaccines and Related Biological Products	11/13/2015	1	20	4	3	13	1	12	92.31%



Committee Name	Meeting Date	Number of Meetings	# of persons contacted (attending and not attending)*	# of persons contacted and not serving due to potential conflicts of interest	# of persons contacted and not serving due to reasons other than potential conflicts of interest	Total Number of Meeting Participants Attending (voting & nonvoting)*	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total meeting Participants with no waivers	% of Meeting Participants Not Issued Waivers
<b>CENTER FOR DRUG EVALUATION AND RESEARCH Cont.</b>									
Dermatologic and Ophthalmic Drugs Advisory Committee	7/19/2016	1	50	2	30	18	0	18	100.00%
Drug Safety and Risk Management Advisory Committee	5/3-4/2016	1	55	2	<del>22</del> 23	30	0	30	100.00%
Endocrinologic and Metabolic Drugs Advisory Committee	12/14/2015	1	21	2	4	15	0	15	100.00%
Endocrinologic and Metabolic Drugs Advisory Committee	5/24/2016	1	34	0	17	17	0	17	100.00%
Endocrinologic and Metabolic Drugs Advisory Committee	5/25/2016	1	33	0	16	17	0	17	100.00%
Endocrinologic and Metabolic Drugs Advisory Committee	6/28/2016	1	40	2	15	23	1	22	95.65%
Gastrointestinal Drugs Advisory Committee (joint w/ Drug Safety and Risk Management Advisory Committee)	4/7/2016	1	32	1	14	17	0	17	100.00%
Nonprescription Drugs Advisory Committee	4/15/2016	1	38	1	21	16	0	16	100.00%
Oncologic Drugs Advisory Committee Pediatric Oncology Subcommittee	11/19/2015	1	21	4	7	10	0	10	100.00%
Oncologic Drugs Advisory Committee	9/14/2016	1	19	1	4	14	0	14	100.00%
Oncologic Drugs Advisory Committee	4/12/2016	1	20	2	4	14	0	14	100.00%
Pediatric Sub-Committee/ODAC	6/28-29/2016	1	25	0	9	16	4	12	75.00%
Peripheral and Central Nervous System Drugs Advisory Committee	11/24/2015	1	32	0	15	17	0	17	100.00%
Peripheral and Central Nervous System Drugs Advisory Committee	4/25/2016	1	17	1	3	13	0	13	100.00%
Pharmaceutical Science and Clinical Pharmacology Advisory Committee	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Pharmacy Compounding Advisory Committee	10/27-28/2015	1	24	0	10	14	0	14	100.00%
Pharmacy Compounding Advisory Committee	3/8-9/2016	1	18	0	6	12	0	12	100.00%
Pharmacy Compounding Advisory Committee	6/23/2016	1	17	1	4	12	0	12	100.00%



Committee Name	Meeting Date	Number of Meetings	# of persons contacted (attending and not attending)*	# of persons contacted and not serving due to potential conflicts of interest	# of persons contacted and not serving due reasons other than potential conflicts of interest	Total Number of Meeting Participants Attending (voting & nonvoting)*	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total meeting Participants with no waivers	% of Meeting Participants Not Issued Waivers
<b>CENTER FOR DEVICES AND RADIOLOGICAL HEALTH Cont.</b>									
Ear, Nose, and Throat Devices Panel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gastroenterology and Urology Devices Panel	2/25-26/2016	1	25	1	10	14	0	14	100.00%
General and Plastic Surgery Devices Panel	9/20-21/2016	1	31	0	15	16	0	16	100.00%
General Hospital and Personal Use Devices Panel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Hematology and Pathology Devices Panel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Immunology Devices Panel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Medical Devices Dispute Resolution Panel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Microbiology Devices Panel	8/16/2016	1	27	1	9	17	0	17	100.00%
Molecular and Clinical Genetics Devices Panel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Neurological Devices Panel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Obstetrics and Gynecology Devices Panel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Ophthalmic Devices Panel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Orthopedic and Rehabilitation Devices Panel	2/19/2016	1	29	1	14	14	0	14	100.00%
Orthopedic and Rehabilitation Devices Panel	4/20/2016	1	22	0	7	15	0	15	100.00%
Radiologic Devices Panel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Technical Electronic Safety Standards Advisory Committee Product Radiation	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
National Mammography Quality Assurance Advisory Committee	9/15/2016	1	13	0	2	11	0	11	100.00%
Patient Engagement Advisory Committee	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
<b>NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH</b>		<b>1</b>	<b>0</b> <b>8</b>	<b>0 (0%)</b>	<b>0</b>	<b>8</b>	<b>0 (0%)</b>	<b>8</b>	<b>100.00%</b>
Science Advisory Board to the National Center for Toxicological Research	11/1-2/2015	1	<b>0</b> <b>8</b>	0	0	8	0	8	100.00%
<b>CENTER FOR TOBACCO PRODUCTS</b>		<b>N/A</b>	<b>N/A</b>	<b>N/A</b>	<b>N/A</b>	<b>N/A</b>	<b>N/A</b>	<b>N/A</b>	<b>N/A</b>
Tobacco Products Scientific Advisory Committee	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
<b>* Not including Industry Representatives, Regular FDA Employees, and Guest Speakers</b>									

# FY 2018

**Table 2 - 712(e)(1)(D) Number of Meetings, Persons Contacted, Persons Contacted Who Did Not Serve, Participants, and Waivers Granted FY 2018**

Committee Name	Meeting Date	Number of Meetings	# of persons contacted (attending and not attending)*	# of persons contacted and not serving due to potential conflicts of interest	# of persons contacted and not serving due reasons other than potential conflicts of interest	Total Number of Meeting Participants Attending (voting & nonvoting)*	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total meeting Participants with no waivers	% of Meeting Participants Not Issued Waivers
<b>FDA TOTAL</b>		<b>55</b> <b>56</b>	<b>1422</b> <b>1449</b>	<b>61 (5%)</b> <b>62 (4%)</b>	<b>490 (32%)</b> <b>499 (34%)</b>	<b>872</b> <b>888</b>	<b>12 (1.9%)</b> <b>(1.4%)</b>	<b>860</b> <b>876</b>	<b>98.62%</b> <b>98.65%</b>
<b>OFFICE OF THE COMMISSIONER</b>		<b>4</b>	<b>101</b>	<b>0 (0%)</b>	<b>31 (31%)</b>	<b>70</b>	<b>0</b>	<b>70</b>	<b>100.00%</b>
Science Board to the Food and Drug Administration	4/23/2018	1	16	0	1	15	0	15	100.00%
Pediatric Advisory Committee(Joint meeting with Endocrinologic and Metabolic Drugs Advisory Committee)	5/11/2018	1	31	0	11	20	0	20	100.00%
Pediatric Advisory Committee	9/20/2018	1	22	0	8	14	0	14	100.00%
Risk Communication Advisory Committee	3/5-6/2018	1	32	0	11	21	0	21	100.00%
<b>CENTER FOR BIOLOGICS EVALUATION &amp; RESEARCH</b>		<b>9</b>	<b>197</b>	<b>6</b>	<b>58</b>	<b>133</b>	<b>0</b>	<b>133</b>	<b>100.00%</b>
Allergenic Products Advisory Committee	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Blood Products Advisory Committee	3/21-22/2018	1	33	4	13	16	0	16	100.00%
Blood Products Advisory Committee	6/22/2018	1	15	0	4	11	0	11	100.00%
Blood Products Advisory Committee	7/18-19/2018	1	29	2	9	18	0	18	100.00%
Blood Products Advisory Committee	11/30-21/1/2017	1	26	0	5	21	0	21	100.00%
Cellular, Tissue and Gene Therapies Advisory Committee	10/12/2017	1	17	0	0	17	0	17	100.00%
Vaccines and Related Biological Products Advisory Committee	10/4/2017	1	17	0	0	17	0	17	100.00%
Vaccines and Related Biological Products Advisory Committee	<del>10/4/2017</del> 11/7/2017	1	44 32	0	4 18	40 14	0	40 14	100.00%
Vaccines and Related Biological Products Advisory Committee	5/17/2018	1	16	0	4	12	0	12	100.00%
Vaccines and Related Biological Products Advisory Committee	3/1/2018	1	15	0	1	14	0	14	100.00%

Committee Name	Meeting Date	Number of Meetings	# of persons contacted (attending and not attending)*	# of persons contacted and not serving due to potential conflicts of interest	# of persons contacted and not serving due reasons other than potential conflicts of interest	Total Number of Meeting Participants Attending (voting & nonvoting)*	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total meeting Participants with no waivers	% of Meeting Participants Not Issued Waivers
<b>CENTER FOR DRUG EVALUATION AND RESEARCH</b>		<b>33</b>	<b>891</b>	<b>31</b>	<b>318</b> <b>322</b>	<b>538</b>	<b>8</b>	<b>530</b>	<b>98.51%</b>
Anesthetic and Analgesic Drug Products Advisory Committee	2/14-15/2018	1	16	1	5	10	0	10	100.00%
Anesthetic and Analgesic Drug Products Advisory Committee	2/14/2018	1	36	1	14	21	0	21	100.00%
Anesthetic and Analgesic Drug Products Advisory Committee	5/22/2018	1	28	0	9	19	0	19	100.00%
Anesthetic and Analgesic Drug Products Advisory Committee	6/26/2018	1	33	0	16	17	0	17	100.00%
Antimicrobial Drugs Advisory Committee	5/2/2018	1	33	1	16	16	0	16	100.00%
Antimicrobial Drugs Advisory Committee	11/16/17	1	18	0	3	15	0	15	100.00%
Antimicrobial Drugs Advisory Committee	1/11/2018	1	17	0	1	16	0	16	100.00%
Antimicrobial Drugs Advisory Committee	5/1/2018	1	24	1	6	17	0	17	100.00%
Antimicrobial Drugs Advisory Committee	7/26/2018	1	22	1	8	13	0	13	100.00%
Antimicrobial Drugs Advisory Committee	8/7/2018	1	40	0	<del>22</del> <del>26</del>	14	0	14	100.00%
Antimicrobial Drugs Advisory Committee	8/8/2018	1	31	0	13	18	0	18	100.00%
Antimicrobial Drugs Advisory Committee	7/12/2018	1	19	2	4	13	0	13	100.00%
Arthritis Advisory Committee	4/23/2018	1	15	0	0	15	0	15	100.00%
Arthritis Advisory Committee	4/24-25/2018	1	26	2	3	21	2	19	90.48%
Bone, Reproductive, and Urologic Drugs Advisory Committee	1/10/2018	1	64	2	43	19	1	<del>19</del> <del>18</del>	94.74%
Bone, Reproductive, and Urologic Drugs Advisory Committee	1/9/2018	1	64	2	43	19	1	<del>19</del> <del>18</del>	94.74%
Bone, Reproductive, and Urologic Drugs Advisory Committee	12/7/2017	1	19	4	0	15	0	15	100.00%
Cardiovascular and Renal Drugs Advisory Committee	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A



Committee Name	Meeting Date	Number of Meetings	# of persons contacted (attending and not attending) *	# of persons contacted and not serving due to potential conflicts of interest	# of persons contacted and not serving due reasons other than potential conflicts of interest	Total Number of Meeting Participants Attending (voting & nonvoting)*	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total meeting Participants with no waivers	% of Meeting Participants Not Issued Waivers
<b>Center for Drug Evaluation and Research (Cont.)</b>									
Dermatologic and Ophthalmic Drugs Advisory Committee	10/13/17	1	12	0	2	10	0	10	100.00%
Drug Safety and Risk Management Advisory Committee	8/3/2018	1	41	3	19	19	0	19	100.00%
Endocrinologic and Metabolic Drugs Advisory Committee	10/18/2017	1	24	1	6	17	0	17	100.00%
Endocrinologic and Metabolic Drugs Advisory Committee	5/10/2018	1	25	2	3	20	0	20	100.00%
Gastrointestinal Drugs Advisory Committee	5/3/2018	1	37	1	12	24	0	24	100.00%
Gastrointestinal Drugs Advisory Committee	3/8/2018	1	31	5	10	16	3	13	81.25%
Medical Imaging Drugs Advisory Committee	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Nonprescription Drugs Advisory Committee	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Oncologic Drugs Advisory Committee	3/7/2018	1	23	0	11	12	0	12	100.00%
Pediatric Sub-Committee/Oncologic Drugs Advisory Committee	6/20/2018	1	20	0	3	17	0	17	100.00%
Peripheral and Central Nervous System Drugs Advisory Committee	4/19/2018	1	23	2	8	13	0	13	100.00%
Pharmaceutical Science and Clinical Pharmacology Advisory Committee	9/20/2018	1	14	0	3	11	0	11	100.00%
Pharmacy Compounding Advisory Committee	11/20-21/2017	1	16	0	0	16	0	16	100.00%
Pharmacy Compounding Advisory Committee	9/12/2018	1	16	0	0	16	1	<del>16</del> 15	93.75%
Psychopharmacologic Drugs Advisory Committee	10/31/2017	1	33	0	14	19	0	19	100.00%
Psychopharmacologic Drugs Advisory Committee	11/1/2017	1	33	0	<del>33</del> 12	21	0	21	100.00%
Psychopharmacologic Drugs Advisory Committee	3/27/2018	1	20	0	8	12	0	12	100.00%
Pulmonary-Allergy Drugs Advisory Committee	7/25/2018	1	18	0	1	17	0	17	100.00%

Committee Name	Meeting Date	Number of Meetings	# of persons contacted (attending and not attending)*	# of persons contacted and not serving due to potential conflicts of interest	# of persons contacted and not serving due to reasons other than potential conflicts of interest	Total Number of Meeting Participants Attending (voting & nonvoting)*	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total meeting Participants with no waivers	% of Meeting Participants <u>Not</u> Issued Waivers
<b>CENTER FOR FOOD SAFETY AND APPLIED NUTRITION</b>	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Food Advisory Committee	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
<b>CENTER FOR DEVICES AND RADIOLOGICAL HEALTH</b>		<b>7</b>	<b>213</b>	<b>24</b>	<b>78</b>	<b>111</b>	<b>4</b>	<b>107</b>	<b>96.40%</b>
Device Good Manufacturing Practice Advisory Committee	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
<b>Medical Devices Advisory Committee (Comprised of 18 Panels)</b>									
Anesthesiology and Respiratory Therapy Devices Panel	6/14/2018	1	31	2	14	15	2	13	86.67%
Circulatory System Devices Panel	6/12/2018	1	39	7	14	18	1	17	94.44%
Clinical Chemistry and Clinical Toxicology Devices Panel	3/29-30/2018	1	29	1	10	18	0	18	100.00%
Dental Products Panel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Ear, Nose, and Throat Devices Panel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gastroenterology and Urology Devices Panel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
General and Plastic Surgery Devices Panel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
General Hospital and Personal Use Devices Panel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Hematology and Pathology Devices Panel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Immunology Devices Panel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Medical Devices Dispute Resolution Panel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Microbiology Devices Panel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Molecular and Clinical Genetics Devices Panel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Neurological Devices Panel	9/27/2018	1	37	10	9	18	1	17	94.44%
Neurological Devices Panel	3/1/2018	1	33	4	14	15	0	15	100.00%
Obstetrics and Gynecology Devices Panel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Ophthalmic Devices Panel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
<u>Patient Engagement Advisory Committee</u>	<u>10/11-12/2017</u>	<u>1</u>	<u>9</u>	<u>0</u>	<u>0</u>	<u>9</u>	<u>0</u>	<u>9</u>	<u>100.00%</u>

Committee Name	Meeting Date	Number of Meetings	# of persons contacted (attending and not attending)*	# of persons contacted and not serving due to potential conflicts of interest	# of persons contacted and not serving due reasons other than potential conflicts of interest	Total Number of Meeting Participants Attending (voting & nonvoting)*	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total meeting Participants with no waivers	% of Meeting Participants Not Issued Waivers
<b>CENTER FOR DEVICES AND RADIOLOGICAL HEALTH Cont.</b>									
Orthopedic and Rehabilitation Devices Panel	12/12/2017	1	35	0	17	18	0	18	100.00%
TEPRSSC	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
National Mammography Quality Assurance Advisory Committee	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Radiologic Devices Panel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
<b>NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH</b>		<b>1</b>	<b>5</b>	<b>0 (0%)</b>	<b>0</b>	<b>5</b>	<b>0 (0%)</b>	<b>5</b>	<b>100.00%</b>
Science Advisory Board to the National Center for Toxicological Research	11/6-7/2017	1	5	0	0	5	0	5	100.00%
<b>CENTER FOR TOBACCO PRODUCTS</b>		<b>2</b>	<b>34</b> <b>42</b>	<b>1</b>	<b>5</b> <b>10</b>	<b>31</b>	<b>0</b>	<b>31</b>	<b>100.00%</b>
Tobacco Products Scientific Advisory Committee	9/13-14/2018	1	16 20	1	5	16	0	16	100.00%
Tobacco Products Scientific Advisory Committee	1/24-25/2018	1	15 22	0	5	15	0	15	100.00%
<b>* Not including Industry Representatives, Regular FDA Employees, and Guest Speakers</b>									

## FY 2019

**Table 2 - 712(e)(1)(D) Number of Meetings, Persons Contacted, Persons Contacted Who Did Not Serve, Participants, and Waivers Granted - FY 2019**

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending) *	# of Persons Contacted and Not Serving Because of Potential Conflicts of Interest	# of Persons contacted and Not Serving Because of Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting)*	18 U.S.C. 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
<b>FDA TOTALS</b>	-----	<b>48</b> <b>49</b>	<b>1295</b> <b>1250</b>	<b>48</b> <b>50</b>	<b>334</b> <b>330</b>	<b>811</b> <b>870</b>	<b>7</b>	<b>863</b>	<b>99.14%</b> <b>99.20%</b>
<b>OFFICE OF THE COMMISSIONER</b>		<b>4</b>	<b>119</b>	<b>1</b>	<b>25</b>	<b>93</b>	<b>0</b>	<b>93</b>	<b>100.00%</b>
Science Board to the Food and Drug Administration	10/22/2018	1	16	0	1	15	0	15	100.00%
Pediatric Advisory Committee	4/8/2019	1	24	0	5	19	0	19	100.00%
Pediatric Advisory Committee	9/26/2019	1	40	1	11	28	0	28	100.00%
Pediatric Advisory Committee	9/27/2019	1	39	0	8	31	0	31	100.00%
<b>CENTER FOR BIOLOGICS EVALUATION &amp; RESEARCH</b>		<b>6</b>	<b>106</b>	<b>3</b>	<b>21</b>	<b>82</b>	<b>1</b>	<b>81</b>	<b>98.78%</b>
Allergenic Products Advisory Committee	9/13/2019	1	11	3	0	8	0	8	100.00%
Blood Products Advisory Committee	3/20-21/2019	1	24	0	6	18	0	18	100.00%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending) *	# of Persons Contacted and Not Serving Because of Potential Conflicts of Interest	# of Persons contacted and Not Serving Because of Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting)*	18 U.S.C. 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
<b>CENTER FOR BIOLOGICS EVALUATION &amp; RESEARCH, CONTINUED...</b>									
Vaccines and Related Biological Products Advisory Committee	10/3/2018	1	15	0	1	14	0	14	100.00%
Vaccines and Related Biological Products Advisory Committee	11/8/2018	1	13	0	4	9	0	9	100.00%
Vaccines and Related Biological Products Advisory Committee	3/6-7/2019	1	22	0	1	21	1	20	95.24%
Vaccines and Related Biological Products Advisory Committee	3/22/2019	1	21	0	9	12	0	12	100.00%
<b>CENTER FOR DRUG EVALUATION &amp; RESEARCH</b>		<b>28</b>	<b><del>754</del> <u>744</u></b>	<b><del>25</del> <u>24</u></b>	<b>180</b>	<b><del>542</del> <u>540</u></b>	<b>6</b>	<b><del>538</del> <u>534</u></b>	<b><del>98.99%</del> <u>99.26%</u></b>
Anesthetic and Analgesic Drug Products Advisory Committee	10/11/18	1	14	0	1	13	0	13	100.00%
Anesthetic and Analgesic Drug Products Advisory Committee	10/12/18	1	13	0	1	12	0	12	100.00%
Anesthetic and Analgesic Drug Products Advisory Committee	11/14/18	1	36	0	19	17	0	17	100.00%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending) *	# of Persons Contacted and Not Serving Because of Potential Conflicts of Interest	# of Persons contacted and Not Serving Because of Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting) *	18 U.S.C. 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
<b>CENTER FOR DRUG EVALUATION &amp; RESEARCH, CONTINUED...</b>									
Anesthetic and Analgesic Drug Products Advisory Committee	11/15/18	1	25	1	11	13	0	13	100.00%
Anesthetic and Analgesic Drug Products Advisory Committee Joint Meeting with DSARM.	12/17-18/2019	1	41	1	14	26	0	26	100.00%
Antimicrobial Drugs Advisory Committee	4/25/19	1	26	0	0	26	0	26	100.00%
Antimicrobial Drugs Advisory Committee	4/26/19	1	29	1	11	17	0	17	100.00%
Antimicrobial Drugs Advisory Committee	6/5/19	1	23	0	0	23	0	23	100.00%
Antimicrobial Drugs Advisory Committee	6/6/19	1	23	0	0	23	0	23	100.00%
Antimicrobial Drugs Advisory Committee	8/7/19	1	24	1	5	18	2	16	88.89%
Arthritis Advisory Committee	1/11/2019	1	28	4	2	22	1	21	95.45%
<u>Arthritis Advisory Committee</u>	<u>7/25/2019</u>	<u>1</u>	<u>23</u>	<u>1</u>	<u>5</u>	<u>17</u>	<u>0</u>	<u>17</u>	<u>100.00%</u>

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending) *	# of Persons Contacted and Not Serving Because of Potential Conflicts of Interest	# of Persons contacted and Not Serving Because of Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting) *	18 U.S.C. 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
<b>CENTER FOR DRUG EVALUATION &amp; RESEARCH, CONTINUED...</b>									
Bone, Reproductive and Urologic Drugs Advisory Committee	1/16/2019	1	33	2	12	19	0	19	100.00%
<del>Bone, Reproductive and Urologic Drugs Advisory Committee</del>	<del>1/16/2019</del>	<del>1</del>	<del>33</del>	<del>2</del>	<del>12</del>	<del>19</del>	<del>0</del>	<del>19</del>	<del>100.00%</del>
Drug Safety and Risk Management Advisory Committee	6/11-12/2019	1	59	0	0	59	0	59	100.00%
Endocrinologic and Metabolic Drugs Advisory Committee	1/17/2019	1	17	0	2	15	0	15	100.00%
Endocrinologic and Metabolic Drugs Advisory Committee	10/24-25/2018	1	28	1	8	19	0	19	100.00%
Gastrointestinal Drugs Advisory Committee	10/18/2018	1	23	1	12	10	1	9	90.00%
Gastrointestinal Drugs Advisory Committee	10/17/2018	1	35	0	23	12	1	11	91.67%

<b>Committee Name</b>	<b>Meeting Date</b>	<b># of Meetings</b>	<b># of Persons Contacted (Attending and Not Attending) *</b>	<b># of Persons Contacted and Not Serving Because of Potential Conflicts of Interest</b>	<b># of Persons contacted and Not Serving Because of Reasons Other Than Potential Conflicts of Interest</b>	<b>Total Number of Meeting Participants Attending (Voting &amp; Nonvoting) *</b>	<b>18 U.S.C. 208(b)(1) and (b)(3) Waivers Granted</b>	<b>Total Meeting Participants with No Waivers</b>	<b>% of Meeting Participants <u>Not</u> Issued Waivers</b>
<b>CENTER FOR DRUG EVALUATION &amp; RESEARCH, CONTINUED...</b>									
Nonprescription Drugs Advisory Committee	9/18/2019	1	21	0	0	21	0	21	100.00%
Oncologic Drugs Advisory Committee	5/14/19	1	29	0	0	29	0	29	100.00%
Oncologic Drugs Advisory Committee	10/10/2018	1	36	1	19	16	0	16	100.00%
Oncologic Drugs Advisory Committee	2/26/2019	1	23	6	3	14	0	14	100.00%
Pediatric Sub-Committee/ODAC	6/20/2019	1	16	2	4	10	1	9	90.00%
Pharmaceutical Science and Clinical Pharmacology Advisory Committee	5/7/19	1	20	1	5	14	0	14	100.00%
Psychopharmacologic Drugs Advisory Committee	11/1/18	1	24	0	1	23	0	23	100.00%
Psychopharmacologic Drugs Advisory Committee	11/2/18	1	21	0	3	18	0	18	100.00%
Psychopharmacologic Drugs Advisory Committee	2/12/19	1	29	1	10	18	0	18	100.00%
Pulmonary-Allergy Drugs Advisory Committee	5/8/19	1	25	0	9	16	0	16	100.00%



<b>Committee Name</b>	<b>Meeting Date</b>	<b># of Meetings</b>	<b># of Persons Contacted (Attending and Not Attending) *</b>	<b># of Persons Contacted and Not Serving Because of Potential Conflicts of Interest</b>	<b># of Persons contacted and Not Serving Because of Reasons Other Than Potential Conflicts of Interest</b>	<b>Total Number of Meeting Participants Attending (Voting &amp; Nonvoting) *</b>	<b>18 U.S.C. 208(b)(1) and (b)(3) Waivers Granted</b>	<b>Total Meeting Participants with No Waivers</b>	<b>% of Meeting Participants <u>Not</u> Issued Waivers</b>
<b>CENTER FOR DEVICES AND RADIOLOGICAL HEALTH</b>		<b>9</b>	<b>258</b>	<b>22</b>	<b>100</b>	<b>136</b>	<b>0</b>	<b>136</b>	<b>100.00%</b>

<b>Medical Devices Advisory Committee (Composed of 18 Panels)</b>									
Circulatory System Devices Panel	12/4-5/2018	1	36	3	13	20	0	20	100.00%
Circulatory System Devices Panel	6/19-20/2019	1	37	4	17	16	0	16	100.00%
General and Plastic Surgery Devices Panel	3/25-26/2019	1	52	4	31	17	0	17	100.00%
General and Plastic Surgery Devices Panel	5/30-31/2019	1	33	0	23	10	0	10	100.00%
Microbiology Devices Panel	3/8/2019	1	23	1	5	17	0	17	100.00%
Neurological Devices Panel	3/21/2019	1	23	0	5	18	0	18	100.00%
Obstetrics and Gynecology Devices Panel	2/12-13/2019	1	28	10	5	13	0	13	100.00%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending) *	# of Persons Contacted and Not Serving Because of Potential Conflicts of Interest	# of Persons Contacted and Not Serving Because of Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting) *	18 U.S.C. 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
<b>CENTER FOR DEVICES AND RADIOLOGICAL HEALTH, CONTINUED...</b>									
Patient Engagement Advisory Committee	9/10/2019	1	13	0	1	12	0	12	100.00%
Patient Engagement Advisory Committee	11/15/2018	1	13	0	0	13	0	13	100.00%
<b>NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH</b>		<b>1</b>	<b>9</b>	<b>0</b>	<b>4</b>	<b>5</b>	<b>0</b>	<b>5</b>	<b>100.00%</b>
Science Advisory Board to the National Center for Toxicological Research	3/19/2019	1	9	0	4	5	0	5	100.00%
<b>CENTER FOR TOBACCO PRODUCTS</b>		<b>1</b>	<b>14</b>	<b>0</b>	<b>0</b>	<b>14</b>	<b>0</b>	<b>14</b>	<b>100.00%</b>
Tobacco Products Scientific Advisory Committee	2/6-7/2019	1	14	0	0	14	0	14	100.00%
* Not including Industry Representatives, Regular FDA Employees, and Guest Speakers									

## FY 2020

**Table 2 - 712(e)(1)(D) Number of Meetings, Persons Contacted, Persons Contacted Who Did Not Serve, Participants, and Waivers Granted - FY 2020**

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending) *	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting) *	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants With No Waivers	% of Meeting Participants <u>Not Issued</u> Waivers
<b>FDA TOTALS</b>	-----	<b>34</b> <b>30</b>	<b>757</b> <b>646</b>	<b>31</b> <b>29</b>	<b>193</b> <b>162</b>	<b>532</b> <b>455</b>	<b>9</b>	<b>523</b> <b>446</b>	<b>98.31%</b> <b>98.02%</b>
<b>OFFICE OF THE COMMISSIONER</b>		2	39	0	0 1	38	1	37	97.37%
Science Board to the Food and Drug Administration	10/7/2019	1	15	0	0 1	14	0	14	100.00%
Pediatric Advisory Committee	9/15/2020	1	24	0	0	24	1	23	95.83%
<b>CENTER FOR BIOLOGICS EVALUATION &amp; RESEARCH</b>		5	74	4	16	54	0	54	100.00%
Allergenic Products Advisory Committee	11/22/2019	1	15	2	2	11	0	11	100.00%
Blood Products Advisory Committee	5/8/2020	1	15	0	1	14	0	14	100.00%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending) *	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting) *	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants With No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
<b>CENTER FOR BIOLOGICS EVALUATION &amp; RESEARCH, CONTIUNED...</b>									
Vaccines and Related Biological Products Advisory Committee	10/9/2019	1	16	0	7	9	0	9	100.00%
Vaccines and Related Biological Products Advisory Committee	11/8/2019	1	14	2	4	8	0	8	100.00%
Vaccines and Related Biological Products Advisory Committee	3/4/2020	1	14	0	2	12	0	12	100.00%
<b>CENTER FOR DRUG EVALUATION &amp; RESEARCH</b>		<b><u>21</u> <u>17</u></b>	<b><u>513</u> <u>402</u></b>	<b><u>20</u> <u>18</u></b>	<b><u>145</u> <u>113</u></b>	<b><u>348</u> <u>271</u></b>	<b>6</b>	<b><u>342</u> <u>265</u></b>	<b><u>98.28%</u> <u>97.79%</u></b>
Anesthetic and Analgesic Drug Products Advisory Committee	1/16/20	1	15	1	2	12	0	12	100.00%
Anesthetic and Analgesic Drug Products Advisory Committee Joint Meeting with DSARMAC	1/14/20	1	45	0	18	27	0	27	100.00%
Anesthetic and Analgesic Drug Products Advisory Committee Joint Meeting with DSARMAC	1/15/20	1	40	0	14	26	0	26	100.00%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending) *	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting) *	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants With No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
<b>CENTER FOR DRUG EVALUATION &amp; RESEARCH, CONTINUED...</b>									
<del>Anesthetic and Analgesic Drug Products Advisory Committee Joint Meeting with DSARMAC</del>	<del>1/15/20</del>	<del>1</del>	<del>41</del>	<del>0</del>	<del>15</del>	<del>26</del>	<del>0</del>	<del>26</del>	<del>100.00%</del>
<del>DSARM with Anesthetic and Analgesic Drug Products Advisory Committee Joint Meeting</del>	<del>1/15/20</del>	<del>1</del>	<del>35</del>	<del>1</del>	<del>6</del>	<del>28</del>	<del>0</del>	<del>28</del>	<del>100.00%</del>
Antimicrobial Drugs Advisory Committee	10/16/19	1	25	0	9	16	0	16	100.00%
Bone, Reproductive, and Urologic Drugs Advisory Committee	10/29/2019	1	29	2	11	16	0	16	100.00%
Bone, Reproductive, and Urologic Drugs Advisory Committee	10/30/2019	1	32	3	12	17	1	16	94.12%
Cardiovascular and Renal Drugs Advisory Committee	7/15/2020	1	17	1	1	15	0	15	100.00%
Cardiovascular and Renal Drugs Advisory Committee	12/10/2019	1	17	1	2	14	0	14	100.00%
Endocrinologic and Metabolic Drugs Advisory Committee	11/13/2019	1	16	0	0	16	0	16	100.00%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending) *	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting) *	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants With No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
<b>CENTER FOR DRUG EVALUATION &amp; RESEARCH, CONTINUED...</b>									
Endocrinologic and Metabolic Drugs Advisory Committee	11/14/2019	1	20	0	4	16	0	16	100.00%
<del>Oncologic Drugs Advisory Committee</del>	<del>12/17/2020</del>	<del>1</del>	<del>14</del>	<del>0</del>	<del>2</del>	<del>12</del>	<del>0</del>	<del>12</del>	<del>100.00%</del>
Oncologic Drugs Advisory Committee	12/17/ <del>2020</del> <u>2019</u>	1	19	2	3	14	0	14	100.00%
Oncologic Drugs Advisory Committee	12/18/ <del>2020</del> <u>2019</u>	1	17	3	3	11	0	11	100.00%
Oncologic Drugs Advisory Committee	2/26/20	1	26	2	9	15	0	15	100.00%
<del>Oncologic Drugs Advisory Committee</del>	<del>2/26/20</del>	<del>1</del>	<del>21</del>	<del>1</del>	<del>9</del>	<del>11</del>	<del>0</del>	<del>11</del>	<del>100.00%</del>
Oncologic Drugs Advisory Committee	7/14/2020	1	21	2	5	14	0	14	100.00%







Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending) *	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting) *	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants With No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
<b>NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH</b>		2	18	0	0	18	0	18	100.00%
Science Advisory Board to the National Center for Toxicological Research	8/18-19/2020	1	9	0	0	9	0	9	100.00%
Science Advisory Board to the National Center for Toxicological Research	12/3-4/2019	1	9	0	0	9	0	9	100.00%
<b>CENTER FOR TOBACCO PRODUCTS</b>		1	14	0	0	14	0	14	100.00%
Tobacco Products Scientific Advisory Committee	2/14/2020	1	14	0	0	14	0	14	100.00%

\* Not including Industry Representatives, Regular FDA Employees, and Guest Speakers

## FY 2021

**Table 2 – FY 2021’s Section 712(e)(1)(D) Number of Meetings, Persons Contacted, Persons Contacted Who Did Not Serve, Participants, and Waivers Granted**

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending) *	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting)*	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not Issued</u> Waivers
<b>FDA’s Totals</b>	-----	<b>37</b>	<del><b>336</b></del> <b>890</b>	<del><b>61</b></del> <b>73</b>	<del><b>121</b></del> <b>160</b>	<del><b>654</b></del> <b>657</b>	<b>26</b>	<del><b>632</b></del> <b>631</b>	<del><b>96.64%</b></del> <b>96.04%</b>
<b>Center for Biologics Evaluation &amp; Research</b>		<b>11</b>	<b>270</b>	<b>18</b>	<b>34</b>	<b>218</b>	<b>11</b>	<b>207</b>	<b>94.95%</b>
Cellular, Tissue and Gene Therapies Advisory Committee	4/15/2021	1	19	1	2	16	0	16	100.00%
Cellular, Tissue and Gene Therapies Advisory Committee	9/2-3/2021	1	25	2	1	22	4	18	81.82%
Vaccines and Related Biological Products Advisory Committee	10/2/2020	1	15	0	0	15	0	15	100.00%
Vaccines and Related Biological Products Advisory Committee	10/22/2020	1	29	6	1	22	2	20	90.91%
Vaccines and Related Biological Products Advisory Committee	12/10/2020	1	35	0	8	27	1	26	96.30%
Vaccines and Related Biological Products Advisory Committee	12/17/2020	1	34	0	7	27	1	26	96.30%
Vaccines and Related Biological Products Advisory Committee	2/26/2021	1	27	0	7	20	1	19	95.00%
Vaccines and Related Biological Products Advisory Committee	3/5/2021	1	16	0	0	16	0	16	100.00%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending) *	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting)*	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not Issued</u> Waivers
Vaccines and Related Biological Products Advisory Committee	6/10/2021	1	26	0	6	20	1	19	95.00%
Vaccines and Related Biological Products Advisory Committee	9/17/2021	1	28	9	1	18	1	17	94.00%
Vaccines and Related Biological Products Advisory Committee	9/30/2021	1	16	0	1	15	0	15	100.00%
<b>Center for Devices &amp; Radiological Health</b>		<b>9</b>	<b>237</b>	<b>21</b>	<del>56</del> <u>57</u>	<b>159</b>	<del>2</del> <u>1</u>	<del>157</del> <u>158</u>	<b>98.74%</b>
<b>Medical Devices Advisory Committee</b>									
Circulatory System Devices Panel	10/27/2021	1	25	0	5	20	0	20	100.00%
Circulatory System Devices Panel	2/17/2021	1	32	3	8	21	0	21	100.00%
Circulatory System Devices Panel	4/6/2021	1	26	2	2	22	0	22	100.00%
Circulatory System Devices Panel	8/3/2021	1	28	2	6	20	0	20	100.00%
Gastroenterology and Urology Devices Panel	7/14/2021	1	45	13	15	17	1	16	94.12%
General and Plastic Surgery Devices Panel	3/23/2021	1	22	0	9	13	0	13	100.00%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending) *	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting)*	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not Issued</u> Waivers
Neurological Devices Panel	6/3-4/2021	1	20	0	3	17	0	17	100.00%
Ophthalmic Devices Panel	11/9/2020	1	28	1	8	19	0	19	100.00%
Patient Engagement Advisory Committee	10/22/2020	1	11	0	1	10	0	10	100.00%
<b>Center for Drug Evaluation &amp; Research</b>		<b>15</b>	<b>356</b>	<b>34</b>	<b>67</b>	<b>255</b>	<b>14</b>	<b>241</b>	<b>94.51%</b>
Anesthetic and Analgesic Drug Products Advisory Committee Joint Meeting With DSaRM	11/2/2020	1	27	4	2	21	0	21	100.00%
Arthritis Advisory Committee Joint Meeting With DSaRM	3/24-25/2021	1	36	3	13	20	0	20	100.00%
Arthritis Advisory Committee	5/6/2021	1	22	0	4	18	1	17	94.44%
Cardiovascular and Renal Drugs Advisory Committee	12/15/2020	1	15	1	1	13	0	13	100.00%
Cardiovascular and Renal Drugs Advisory Committee	12/16/2020	1	15	1	1	13	0	13	100.00%
Cardiovascular and Renal Drugs Advisory Committee	7/15/2021	1	20	1	5	14	1	13	92.86%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending) *	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting)*	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not Issued</u> Waivers
Endocrinologic and Metabolic Drugs Advisory Committee	5/27/2021	1	21	0	4	17	0	17	100.00%
Oncologic Drugs Advisory Committee	2/9/2021	1	22	9	3	10	4	6	60.00%
Oncologic Drugs Advisory Committee	4/27-29/2021	1	44	11	12	21	6	15	71.43%
Oncologic Drugs Advisory Committee	6/24/2021	1	20	2	1	17	0	17	100.00%
Pediatric Sub-Committee of the Oncologic Drugs Advisory Committee	5/11-12/2021	1	21	1	2	18	0	18	100.00%
Peripheral and Central Nervous System Drugs Advisory Committee	11/6/2020	1	14	0	3	11	0	11	100.00%
Pharmacy Compounding Advisory Committee	6/9/2021	1	17	0	0	17	2	15	88.24%
Psychopharmacologic Drugs Advisory Committee/Drug Safety and Risk Management	10/8/2020	1	34	0	11	23	0	23	100.00%
Psychopharmacologic Drugs Advisory Committee/Drug Safety and Risk Management	10/9/2020	1	28	1	5	22	0	22	100.00%

<b>Committee Name</b>	<b>Meeting Date</b>	<b># of Meetings</b>	<b># of Persons Contacted (Attending and Not Attending) *</b>	<b># of Persons Contacted and Not Serving Due to Potential Conflicts of Interest</b>	<b># of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest</b>	<b>Total Number of Meeting Participants Attending (Voting &amp; Nonvoting)*</b>	<b>18 USC 208(b)(1) and (b)(3) Waivers Granted</b>	<b>Total Meeting Participants with No Waivers</b>	<b>% of Meeting Participants <u>Not Issued</u> Waivers</b>
<b>National Center for Toxicological Research</b>		<b>1</b>	<b>8</b>	<b>0</b>	<b>0</b>	<b>8</b>	<b>0</b>	<b>8</b>	<b>100.00%</b>
Science Advisory Board to the National Center for Toxicological Research	5/11-12/2021	1	8	0	0	8	0	8	100.00%
<b>Office of the Commissioner</b>		<b>1</b>	<b>19</b>	<b>0</b>	<b>2</b>	<b>17</b>	<b>0</b>	<b>17</b>	<b>100.00%</b>
Pediatric Advisory Committee	9/17/2021	1	19	0	2	17	0	17	100.00%
* Not including industry representatives, FDA employees, and guest speakers									

## FY 2022

**Table 2 – FY 2022’s Section 712(e)(1)(D) Number of Meetings, Persons Contacted, Persons Contacted Who Did Not Serve, Participants, and Waivers Granted**

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending)*	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons contacted and Not Serving due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting)*	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
<b>FDA TOTALS</b>	-----	<b>35</b>	<b>819</b>	<b>54</b>	<b>193</b>	<b>572</b>	<b>22</b>	<b>550</b>	<b>96.15%</b>
<b>Office of the Commissioner</b>		<b>1</b>	<b>13</b>	<b>1</b>	<b>0</b>	<b>12</b>	<b>0</b>	<b>12</b>	<b>100.00%</b>
Science Board to the Food and Drug Administration	6/14/2022	1	13	1	0	12	0	12	100.00%
<b>Center for Biologics Evaluation &amp; Research</b>		<b>13</b>	<b>306</b>	<b>30</b>	<b>36</b>	<b>240</b>	<b>5</b>	<b>235</b>	<b>97.92%</b>
Allergenic Products Advisory Committee	10/28/2021	1	16	0	0	16	0	16	100.00%
Blood Products Advisory Committee	11/4/2021	1	19	0	4	15	0	15	100.00%
Cellular, Tissue and Gene Therapies Advisory Committee	3/10/2022	1	13	0	2	11	0	11	100.00%
Cellular, Tissue and Gene Therapies Advisory Committee	6/9-10/2022	1	26	2	4	20	0	20	100.00%
Cellular, Tissue and Gene Therapies Advisory Committee	6/29-30/2022	1	23	0	5	18	0	18	100.00%
Vaccines and Related Biological Products Advisory Committee	10/14-15/2021	1	28	6	2	20	1	19	95.00%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending)*	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons contacted and Not Serving due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting)*	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants Not Issued Waivers
Vaccines and Related Biological Products Advisory Committee	10/26/2021	1	28	6	2	20	1	19	95.00%
Vaccines and Related Biological Products Advisory Committee	3/3/2022	1	19	0	5	14	0	14	100.00%
Vaccines and Related Biological Products Advisory Committee	4/6/2022	1	28	4	4	20	1	19	95.00%
Vaccines and Related Biological Products Advisory Committee	6/7/2022	1	28	5	1	22	0	22	100.00%
Vaccines and Related Biological Products Advisory Committee	6/14-15/2022	1	28	4	0	24	1	23	95.83%
Vaccines and Related Biological Products Advisory Committee	6/28/2022	1	30	3	5	22	1	21	95.45%
Vaccines and Related Biological Products Advisory Committee	9/22/2022	1	20	0	2	18	0	18	100.00%
<b>Center for Drug Evaluation &amp; Research</b>		<b>13</b>	<b>330</b>	<b>12</b>	<b>107</b>	<b>211</b>	<b>10</b>	<b>201</b>	<b>95.26%</b>
Antimicrobial Drugs Advisory Committee	10/7/2021	1	24	5	2	17	0	17	100.00%
Antimicrobial Drugs Advisory Committee	11/30/2021	1	29	1	5	23	0	23	100.00%



Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending)*	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons contacted and Not Serving due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting)*	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
Cardiovascular and Renal Drugs Advisory Committee	12/8/2021	1	20	0	7	13	0	13	100.00%
Anesthetic and Analgesic Drug Advisory Committee/Drug Safety and Risk Management Advisory Committee (joint meeting)	2/15/2022	1	25	1	2	22	0	22	100.00%
Oncologic Drugs Advisory Committee	2/10/2022	1	<del>20</del> 25	1	9	15	2	13	86.67%
Oncologic Drugs Advisory Committee	4/21-22/2022	1	26	0	9	17	0	17	100.00%
Oncologic Drugs Advisory Committee	9/22-23/2022	1	39	2	14	23	5	18	78.26%
Pediatric Sub-Committee of the Oncologic Drugs Advisory Committee	5/11-12/2022	1	19	0	3	16	0	16	100.00%
Peripheral and Central Nervous System Drugs Advisory Committee	3/30/2022	1	18	0	8	10	0	10	100.00%
Peripheral and Central Nervous System Drugs Advisory Committee	9/7/2022	1	11	0	2	9	0	9	100.00%
Pharmacy Compounding Advisory Committee	6/8/2022	1	49	1	27	21	2	19	90.48%
Psychopharmacologic Drugs Advisory Committee	11/4/2021	1	21	0	8	13	0	13	100.00%
Psychopharmacologic Drugs Advisory Committee	6/17/2022	1	24	1	11	12	1	11	91.67%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending)*	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons contacted and Not Serving due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting)*	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants Not Issued Waivers
<b>Center for Devices &amp; Radiological Health</b>		<b>7</b>	<b>161</b>	<b>11</b>	<b>50</b>	<b>100</b>	<b>7</b>	<b>93</b>	<b>93.00%</b>
Device Good Manufacturing Practice Advisory Committee	3/2/2022	1	7	0	0	7	0	7	100.00%
Circulatory System Devices Panel	11/2-3/2021	1	28	6	3	19	5	14	73.68%
General and Plastic Surgery Devices Panel	10/20/2021	1	30	1	14	15	0	15	100.00%
General and Plastic Surgery Devices Panel	7/28-29/2022	1	44	2	24	18	0	18	100.00%
Neurological Devices Panel	12/10/2021	1	23	2	5	16	0	16	100.00%
Patient Engagement Advisory Committee	10/6/2021	1	12	0	1	11	1	10	90.91%
Patient Engagement Advisory Committee	7/12-13/2022	1	17	0	3	14	1	13	92.86%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending)*	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting)*	18 USC 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
<b>National Center for Toxicological Research</b>		<b>1</b>	<b>9</b>	<b>0</b>	<b>0</b>	<b>9</b>	<b>0</b>	<b>9</b>	<b>100.00%</b>
Science Advisory Board to the National Center for Toxicological Research	5/18-19/2022	1	9	0	0	9	0	9	100.00%
<b>Center for Tobacco Products</b>		<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
Tobacco Products Scientific Advisory Committee									
* Not including Industry Representatives, Regular FDA Employees, and Guest Speakers									

## FY2023

**Table 2 – FY 2023’s Section 712(e)(1)(D) Number of Meetings, Persons Contacted, Persons Contacted Who Did Not Serve, Participants, and Waivers Granted**

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending)*	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting)*	18 U.S.C. 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
<b>FDA’s TOTALS</b>	-----	<b>53</b>	<b>1340</b>	<b>73</b>	<del>441</del> <u>439</u>	<del>826</del> <u>828</u>	<b>23</b>	<del>803</del> <u>804</u>	<del>97.22%</del> <u>97.10%</u>
<b>Office of the Commissioner</b>		<del>4</del> <u>2</u>	<del>13</del> <u>45</u>	<del>1</del> <u>0</u>	<del>9</del> <u>7</u>	<del>12</del> <u>38</u>	<b>0</b>	<del>12</del> <u>38</u>	<b>100.00%</b>
Science Board to the Food and Drug Administration	12/8/2022	1	12	0	0	12	0	12	100.00%
Pediatric Advisory Committee	9/19/2023	1	33	0	7	26	0	26	100.00%
<b>Center for Biologics Evaluation and Research</b>		<b>10</b>	<b>242</b>	<b>27</b>	<b>54</b>	<b>161</b>	<b>3</b>	<b>158</b>	<b>98.14%</b>
Cellular, Tissue, and Gene Therapies Advisory Committee	5/12/2023	1	32	6	11	15	0	15	100.00%
Cellular, Tissue, and Gene Therapies Advisory Committee	9/27/2023	1	48	6	22	20	1	19	95.00%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending)*	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting)*	18 U.S.C. 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
Blood Products	12/8/2022	1	18	0	3	15	0	15	100.00%
Blood Products	4/26/2023	1	18	0	3	15	0	15	100.00%
Vaccines and Related Biological Products	10/6/2022	1	17	1	1	15	0	15	100.00%
Vaccines and Related Biological Products	1/26/2023	1	25	4	3	18	1	17	94.44%
Vaccines and Related Biological Products	2/28-3/1/2023	1	20	2	4	14	0	14	100.00%
Vaccines and Related Biological Products	3/7/2023	1	15	0	3	12	0	12	100.00%
Vaccines and Related Biological Products	5/18/2023	1	22	4	3	15	0	15	100.00%
Vaccines and Related Biological Products	6/15/2023	1	27	4	1	22	1	21	95.45%
<del>Vaccines and Related Biological Products</del>	<del>1/26/2023</del>	<del>4</del>	<del>25</del>	<del>4</del>	<del>3</del>	<del>18</del>	<del>1</del>	<del>17</del>	<del>94.44%</del>

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending)*	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting)*	18 U.S.C. 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
<b>Center for Drug Evaluation and Research</b>		<b>31</b>	<b>748</b>	<b>24</b>	<b><u>244</u> <u>242</u></b>	<b><u>480</u> <u>482</u></b>	<b><u>11</u> <u>12</u></b>	<b><u>469</u> <u>470</u></b>	<b><u>97.71%</u> <u>97.51%</u></b>
Anesthetic and Analgesic Drug Products Advisory Committee	4/19/2023	1	16	0	3	13	0	13	100.00%
Obstetrics, Reproductive, and Urologic Drugs Advisory Committee	10/17-19/2022	1	34	0	18	16	0	16	100.00%
<del>Anesthetic and Analgesic Drug Products Advisory Committee</del>	<del>4/19/2023</del>	<del>1</del>	<del>16</del>	<del>0</del>	<del>3</del>	<del>13</del>	<del>0</del>	<del>13</del>	<del>100.00%</del>
<del>Obstetrics, Reproductive, and Urologic Drugs Advisory Committee</del>	<del>10/17-19/2022</del>	<del>1</del>	<del>34</del>	<del>0</del>	<del>18</del>	<del>16</del>	<del>0</del>	<del>16</del>	<del>100.00%</del>
Antimicrobial Drugs Advisory Committee	4/17/2023	1	14	0	1	13	0	13	100.00%
Antimicrobial Drugs Advisory Committee	3/16/2023	1	24	2	4	18	2	16	88.89%
Antimicrobial Drugs Advisory Committee	6/8/2023	1	26	0	4	22	2	20	90.91%

<b>Committee Name</b>	<b>Meeting Date</b>	<b># of Meetings</b>	<b># of Persons Contacted (Attending and Not Attending)*</b>	<b># of Persons Contacted and Not Serving Due to Potential Conflicts of Interest</b>	<b># of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest</b>	<b>Total Number of Meeting Participants Attending (Voting &amp; Nonvoting)*</b>	<b>18 U.S.C. 208(b)(1) and (b)(3) Waivers Granted</b>	<b>Total Meeting Participants with No Waivers</b>	<b>% of Meeting Participants <u>Not</u> Issued Waivers</b>
Antimicrobial Drugs Advisory Committee	1/24/2023	1	19	1	2	16	0	16	100.00%
Cardiovascular and Renal Drugs Advisory Committee	10/26/2022	1	27	1	9	17	0	17	100.00%
Cardiovascular and Renal Drugs Advisory Committee	11/16/2022	1	18	1	3	14	0	14	100.00%
Cardiovascular and Renal Drugs Advisory Committee	12/13/2022	1	17	0	5	12	0	12	100.00%
Cardiovascular and Renal Drugs Advisory Committee	9/13/2023	1	17	0	4	13	0	13	100.00%
Dermatologic and Ophthalmic Drugs Advisory Committee	1/9/2023	1	15	2	5	8	0	8	100.00%
Endocrinologic and Metabolic Drugs Advisory Committee	6/28/2023	1	22	0	7	15	0	15	100.00%
Endocrinologic and Metabolic Drugs Advisory Committee	9/21/2023	1	32	1	11	20	0	20	100.00%

<b>Committee Name</b>	<b>Meeting Date</b>	<b># of Meetings</b>	<b># of Persons Contacted (Attending and Not Attending)*</b>	<b># of Persons Contacted and Not Serving Due to Potential Conflicts of Interest</b>	<b># of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest</b>	<b>Total Number of Meeting Participants Attending (Voting &amp; Nonvoting)*</b>	<b>18 U.S.C. 208(b)(1) and (b)(3) Waivers Granted</b>	<b>Total Meeting Participants with No Waivers</b>	<b>% of Meeting Participants <u>Not</u> Issued Waivers</b>
Gastrointestinal Drugs Advisory Committee	5/19/2023	1	25	1	7	17	3	14	82.35%
Joint meeting- Drug Safety and Risk Management Advisory Committee and the Ophthalmic Drugs Advisory Committee	3/28-29/2023	1	38	0	15	23	0	23	100.00%
Joint Meeting- Nonprescription Drugs Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee	2/15/2023	1	28	1	6	21	0	21	100.00%
Joint Meeting- Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive and Urologic Drugs Advisory Committee	5/9-10/2023	1	28	0	9	19	0	19	100.00%



<b>Committee Name</b>	<b>Meeting Date</b>	<b># of Meetings</b>	<b># of Persons Contacted (Attending and Not Attending)*</b>	<b># of Persons Contacted and Not Serving Due to Potential Conflicts of Interest</b>	<b># of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest</b>	<b>Total Number of Meeting Participants Attending (Voting &amp; Nonvoting)*</b>	<b>18 U.S.C. 208(b)(1) and (b)(3) Waivers Granted</b>	<b>Total Meeting Participants with No Waivers</b>	<b>% of Meeting Participants <u>Not</u> Issued Waivers</b>
Joint Meeting- Psychopharmacologic Drugs Advisory Committee and the Peripheral and Central Nervous System Drugs Advisory Committee	4/14/2023	1	18	2	5	11	1	10	90.91%
Medical Imaging Drugs Advisory Committee	8/1/2023	1	16	0	1	15	0	15	100.00%
Nonprescription Drugs Advisory Committee	9/11-12/2023	1	38	0	21	17	0	17	100.00%
Oncologic Drugs Advisory Committee	10/28/2022	1	38	1	20	17	0	17	100.00%
Oncologic Drugs Advisory Committee	2/9/2023	1	22	0	8	14	1	13	92.86%
Oncologic Drugs Advisory Committee	3/9/2023	1	28	0	14	14	0	14	100.00%
Oncologic Drugs Advisory Committee	4/28/2023	1	27	1	12	14	0	14	100.00%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending)*	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting)*	18 U.S.C. 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee	6/16/2023	1	17	0	3	14	0	14	100.00%
Peripheral and Central Nervous System Drugs Advisory Committee	3/22/2023	1	15	1	4	10	1	9	90.00%
Peripheral and Central Nervous System Drugs Advisory Committee	6/9/2023	1	18	3	8	7	<del>4</del> <u>2</u>	<del>6</del> <u>5</u>	<del>85.71%</del> <u>71.43%</u>
Pharmaceutical Science and Clinical Pharmacology Advisory Committee	11/2-3/2022	1	21	1	<del>4</del> <u>3</u>	17	0	17	100.00%
Pulmonary-Allergy Drugs Advisory Committee	11/8/2022	1	31	2	<del>12</del> <u>11</u>	18	0	18	100.00%
Pulmonary-Allergy Drugs Advisory Committee	11/9/2022	1	23	2	7	14	0	14	100.00%
Pulmonary-Allergy Drugs Advisory Committee	5/11/2023	1	36	1	12	23	0	23	100.00%

Committee Name	Meeting Date	# of Meetings	# of Persons Contacted (Attending and Not Attending)*	# of Persons Contacted and Not Serving Due to Potential Conflicts of Interest	# of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest	Total Number of Meeting Participants Attending (Voting & Nonvoting)*	18 U.S.C. 208(b)(1) and (b)(3) Waivers Granted	Total Meeting Participants with No Waivers	% of Meeting Participants <u>Not</u> Issued Waivers
<b>Center for Devices and Radiological Health</b>		<b>8</b>	<b>287</b>	<b>22</b>	<b>136</b>	<b>129</b>	<b>9</b>	<b>120</b>	<b>93.02%</b>
Anesthesiology Devices Panel	11/1/2022	1	29	0	12	17	1	16	94.12%
Circulatory System Devices Panel	8/22-23/2023	1	41	14	10	17	4	13	76.47%
Clinical Chemistry and Clinical Toxicology Devices Panel	10/20/2022	1	40	2	22	16	0	16	100.00%
General and Plastic Surgery Devices Panel	10/26-27/2023	1	62	2	35	25	1	24	96.00%
Microbiology Devices Panel	9/7-8/2023	1	39	3	20	16	1	15	93.75%
Ophthalmic Devices Panel	11/10/2022	1	18	1	5	12	0	12	100.00%
Orthopedic and Rehabilitation Devices Panel	4/20/2023	1	42	0	30	12	0	12	100.00%
Patient Engagement Advisory Committee	9/6/2023	1	16	0	2	14	2	12	85.71%

<b>Committee Name</b>	<b>Meeting Date</b>	<b># of Meetings</b>	<b># of Persons Contacted (Attending and Not Attending)*</b>	<b># of Persons Contacted and Not Serving Due to Potential Conflicts of Interest</b>	<b># of Persons Contacted and Not Serving Due to Reasons Other Than Potential Conflicts of Interest</b>	<b>Total Number of Meeting Participants Attending (Voting &amp; Nonvoting)*</b>	<b>18 U.S.C. 208(b)(1) and (b)(3) Waivers Granted</b>	<b>Total Meeting Participants with No Waivers</b>	<b>% of Meeting Participants <u>Not</u> Issued Waivers</b>
<b>National Center for Toxicological Research</b>		<b>1</b>	<b>9</b>	<b>0</b>	<b>0</b>	<b>9</b>	<b>0</b>	<b>9</b>	<b>100.00%</b>
Science Advisory Board to the National Center for Toxicological Research	4/4-5/2023	1	9	0	0	9	0	9	100.00%
<b>Center for Tobacco Products</b>		<b>1</b>	<b>9</b>	<b>0</b>	<b>0</b>	<b>9</b>	<b>0</b>	<b>9</b>	<b>100.00%</b>
Tobacco Products Scientific Advisory Committee	5/18/2023	1	9	0	0	9	0	9	100.00%